Allurion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in the 34^th Annual Oppenheimer Healthcare MedTech & Services Conference, taking place on March 12 - 13, 2024, virtually. Shantanu Gaur, Allurion’s Chief Executive Officer, and Chris Geberth, Chief Financial Officer, will present today, Wednesday, March 13, 2024 at 4:00 p.m. Eastern Time. Management will also participate in 1x1 meetings.

A live webcast of the event will be available on the Allurion website, under Events & Presentations. You can also register for the live webcast here.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan, whether it is gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240313567417/en/

Global Media

Cedric Damour

PR Manager

+33 7 84 21 02 20

cdamour@allurion.com



Investors

Mike Cavanaugh, Investor Relations

ICR Westwicke

(617) 877-9641

mike.cavanaugh@westwicke.com

Source: Allurion Technologies, Inc.